✦ LIBER ✦

New, Selective Catechol-O-Methyltransferase Inhibitors as Therapeutic Agents in Parkinson’s Disease

✍ Scribed by Vincenzo Bonifati; Giuseppe Meco

Book ID: 114129510
Publisher: Elsevier Science
Year: 1999
Tongue: English
Weight: 405 KB
Volume: 81
Category: Article
ISSN: 0163-7258
DOI: 10.1016/s0163-7258(98)00032-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Catechol-O-methyltransferase inhibitors

Catechol-O-methyltransferase inhibitors in Parkinson's disease

✍ J Harper; B Vieira 📂 Article 📅 1998 🏛 The Lancet 🌐 English ⚖ 18 KB

Catechol-O-methyltransferase inhibitors

Catechol-O-methyltransferase inhibitors in Parkinson's disease

✍ Colm Henry; JA Wilson 📂 Article 📅 1998 🏛 The Lancet 🌐 English ⚖ 54 KB

Catechol-O-methyltransferase inhibitors

Catechol-O-methyltransferase inhibitors in Parkinson's disease

✍ Tao Xie; Shu-Leong Ho; David Ramsden 📂 Article 📅 1998 🏛 The Lancet 🌐 English ⚖ 46 KB

Catechol-O-methyltransferase inhibitors

Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease

✍ John G Nutt 📂 Article 📅 1998 🏛 The Lancet 🌐 English ⚖ 49 KB

Tolcapone, a Selective Catechol-O-Methyl

Tolcapone, a Selective Catechol-O-Methyltransferase Inhibitor for Treatment of Parkinson's Disease

✍ David R. P. Guay 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

Catechol-O-methyltransferase inhibitors:

Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease

✍ Jasper Dingemanse 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 305 KB 👁 2 views

Substitution therapy with levodopa and a peripheral inhibitor of aromatic L-amino acid decarboxylase (AADC) is the cornerstone in the treatment of Parkinson's disease. Chronic therapy with levodopa, however, is associated with the occurrence of motor complications that are partially related to the p